Natera Inc (NTRA) Stock Price, Quote & News

Company Profile

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provi...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 980 9190

Website: www.natera.com

Address:

13011 McCallen Pass, Building A Suite 100, Austin, United States

SM07 Jun. 18 at 1:50 PM

$NTRA This is another C Wood’s super hyped stock with a SP doomed to collapse all of a sudden.

2 · Reply

Georgii Jun. 18 at 8:10 AM

$NTRA

0 · Reply

JFDI Jun. 17 at 7:01 PM

$NTRA B/O

0 · Reply

Bio4 Jun. 17 at 6:05 PM

$CYDY $NTRA https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-nateras-cytodyn-ctdna-tie-up-and-board-refresh-reframing/amp

4 · Reply

JFDI Jun. 17 at 1:59 PM

$IBB $VRTX breaking out, AMGN & ILMN tee’d up on the 10d. $RVMD & $NTRA gorgeous sets up here. IBB & XBI looking good. Catalyst? Probably Ai.. ?

1 · Reply

FibonacciTrader_ Jun. 16 at 9:19 PM

Position trading is really just discipline + rotation, nothing else. Get in early -before the crowd calls it a “theme” Rotate from weak structure into strong leadership Always keep a live, evolving watchlist Nobody was chasing names like $HUT $WULF $CIFR ,when they were quietly building bases. Now the narrative is “extended”… which usually happens right before capital rotates elsewhere. Meanwhile, new relative strength is already showing up in $BE $NTRA This game is about staying ahead of narrative fatigue, not chasing it after the move is obvious.

1 · Reply

MorganHoratio Jun. 16 at 7:36 PM

Stocks showing strength $BE $NTRA $GNRC $APLD $RDDT $APLD (Applied Digital) delivered an epic milestone on June 9, securing a landmark 15-year, $5.2B take-or-pay lease for 210 MW with a top hyperscaler, immediately flanked by a $1.59B senior note expansion. Concurrently, $BE (Bloom Energy) just dropped its Mid-Year Report revealing 61% of developers are shifting to onsite microgrids, while backup power giant $GNRC locked down a new Illinois gigafactory on June 15 to massively upscale its large-megawatt (MW) enclosure assembly for critical data centers. Precision medicine titan $NTRA is trading at all-time highs following a June 4 colorectal cancer partnership, while $RDDT commands intense volume within its structural right-side channel. Are you chasing the premium momentum of newly funded, hyperscale-anchored infrastructure pure-play $APLD, or accumulating the defensive, data-center backlogged fortress of manufacturing titan $GNRC on this breakout?

0 · Reply

B2iDigital Jun. 16 at 3:16 AM

Phio Pharmaceuticals Corp. PH-762 silences PD-1 inside a tumor to help the immune system attack cancer. Robert Bitterman, President and CEO of Phio Pharmaceuticals Corp. (NASDAQ: $PHIO ), used a Force Family Office webinar to explain how the company's lead candidate, PH-762, works. The drug targets PD-1, a protein that tumors use to switch off the immune system's T cells, by silencing the gene that produces it so those T cells can recognize the tumor and attack it. Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/phio-pharmaceuticals Bitterman walked through what happens once PH-762 is injected: "...what we do is we're turning off the signal from the gene that's producing the protein, the PD-1. In the absence of PD-1, the T-cells have the ability to basically recover, to reinvigorate, and to go about recognizing the tumor and attack it, which is what a normal healthy immune system will do to a foreign invader." The webinar also covered: • PH-762 as a short interfering RNA (siRNA) injected directly into a tumor, part of Phio's INTASYL® platform • How silencing PD-1 is designed to reinvigorate T cells so they recognize and attack the tumor • Dr. Mary Spellman's point that treating locally right at the lesion and may mean fewer systemic side effects • Bitterman's comparison of the approach to shutting off a water faucet at its source Watch the full presentation: https://youtu.be/QTVd5xDCgGE Phio Pharmaceuticals is a clinical stage biotechnology company developing immuno oncology therapeutics using its INTASYL® self delivering RNAi platform, led by President and CEO Robert Bitterman. Its lead candidate, PH-762, silences designated genes to make immune cells more effective against cancer cells. Learn more at https://phiopharma.com. For investor information, visit https://phiopharma.com/investors/. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EXAS, $NTRA, $GH, $XBI

2 · Reply

TheBullishTrade Jun. 15 at 3:24 PM

$HNGE $GH $NTRA $NBIS $KOPN Every stock experiences pullbacks at some point. As a shareholder, those periods can be frustrating, especially when your thesis remains intact but the market doesn’t agree with you in the short term. However, when a stock becomes excessively oversold and the underlying fundamentals remain strong, sentiment often shifts, and the market eventually recognizes its value. Patience is often required while waiting for that disconnect between price and fundamentals to correct itself. This was back in April when these stocks are pulling back big time and just reclaimed 52 weeks high in just a little over 1 month. Crazy reversal.

0 · Reply

Estimize Jun. 15 at 11:06 AM

Wall St is expecting -0.49 EPS for $NTRA Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/ntra?chart=historical&metric_name=eps&utm_c

0 · Reply

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

2026-06-11T20:15:54.000Z - 7 days ago

Natera resumed with an Outperform at RBC Capital

Jun 11, 2026, 2:30 PM EDT - 7 days ago

Natera Transcript: AGM 2026

Jun 8, 2026, 9:20 AM EDT - 10 days ago

Natera Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-05T08:35:07.000Z - 13 days ago

Natera initiated with a Neutral at Goldman Sachs

2026-06-04T12:17:39.000Z - 14 days ago

Natera, CytoDyn collaborate to advance ctDNA-guided development

Jun 4, 2026, 8:00 AM EDT - 14 days ago

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

2026-06-03T13:15:42.000Z - 15 days ago

Natera appoints Lynch, Rubin to board of directors

Jun 3, 2026, 8:00 AM EDT - 15 days ago

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

2026-06-01T20:52:08.000Z - 17 days ago

Natera assumed with an Outperform at Wolfe Research

2026-06-01T16:20:10.000Z - 17 days ago

CareDx denied request to Supreme Court to revive Natera award

CDNA

2026-05-29T10:07:06.000Z - 20 days ago

Natera announces collaboration with Diakonos Oncology for Signatera in RM

$Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma$

May 29, 2026, 6:00 AM EDT - 20 days ago

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

2026-05-28T10:25:18.000Z - 21 days ago

Natera enrolls first patients in SIGNAL-ER 101 study

May 28, 2026, 6:00 AM EDT - 21 days ago

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

May 26, 2026, 6:00 AM EDT - 23 days ago

Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

May 21, 2026, 5:05 PM EDT - 4 weeks ago

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

2026-05-21T11:18:39.000Z - 4 weeks ago

Natera announces expansion into Austin, creating largest sequencing factory

May 21, 2026, 7:00 AM EDT - 4 weeks ago

Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World

2026-05-20T11:07:32.000Z - 4 weeks ago

Natera announces Expand trial enrolled over 2,000 patients

May 20, 2026, 7:00 AM EDT - 4 weeks ago

EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled

2026-05-15T17:02:31.000Z - 4 weeks ago

Signatera CDx approved by FDA as companion diagnostic in MIBC

May 15, 2026, 12:45 PM EDT - 4 weeks ago

Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

May 14, 2026, 5:30 AM EDT - 5 weeks ago

The Cancer Test That Wall Street Is Betting On

2026-05-14T01:35:09.000Z - 5 weeks ago

Cathie Wood’s ARK Investment buys 17.3K shares of Natera today

2026-05-12T11:15:02.000Z - 5 weeks ago

Natera price target raised to $249 from $240 at Piper Sandler

May 10, 2026, 2:30 PM EDT - 5 weeks ago

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

EW ISRG LLY NVO

2026-05-08T18:12:13.000Z - 5 weeks ago

Natera price target raised to $270 from $250 at Evercore ISI

2026-05-08T16:24:15.000Z - 5 weeks ago

Natera price target raised to $265 from $257 at Baird

2026-05-08T13:32:55.000Z - 5 weeks ago

Natera price target raised to $265 from $260 at JPMorgan

2026-05-08T12:34:01.000Z - 5 weeks ago

Natera price target raised to $265 from $260 at JPMorgan

2026-05-08T12:23:32.000Z - 5 weeks ago

Natera price target raised to $220 from $215 at Wells Fargo

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Natera Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Natera Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Natera Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Natera Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 6 weeks ago

Natera Reports First Quarter 2026 Financial Results

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Natera to Report its First Quarter Results on May 7, 2026

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Natera Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Natera Proxy statement: Proxy filing

Apr 22, 2026, 9:00 AM EDT - 2 months ago

Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

ALLO

Apr 9, 2026, 6:00 AM EDT - 2 months ago

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

Apr 7, 2026, 6:00 AM EDT - 2 months ago

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform

Mar 31, 2026, 6:00 AM EDT - 2 months ago

SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery

Mar 16, 2026, 6:00 AM EDT - 3 months ago

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

Mar 12, 2026, 8:00 AM EDT - 3 months ago

MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

Mar 12, 2026, 8:00 AM EDT - 3 months ago

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Natera Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 1:05 PM EST - 3 months ago

Natera Transcript: 47th Annual Raymond James Institutional Investor Conference

Feb 27, 2026, 10:05 AM EST - 3 months ago

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

Feb 26, 2026, 4:30 PM EST - 4 months ago

Natera Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Natera Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Natera Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Natera Slides: Q4 2025

Feb 26, 2026, 4:05 PM EST - 4 months ago

Natera Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 24, 2026, 6:00 AM EST - 4 months ago

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

Feb 17, 2026, 9:00 AM EST - 4 months ago

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

Feb 6, 2026, 6:00 AM EST - 4 months ago

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Feb 2, 2026, 6:00 AM EST - 4 months ago

Natera Submits Signatera™ CDx PMA to FDA

Jan 28, 2026, 8:00 AM EST - 5 months ago

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

Jan 26, 2026, 6:00 AM EST - 5 months ago

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

Jan 21, 2026, 6:00 AM EST - 5 months ago

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

Jan 20, 2026, 6:00 AM EST - 5 months ago

Natera's Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

Jan 13, 2026, 7:30 PM EST - 5 months ago

Natera Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 5 months ago

Natera Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 8:00 AM EST - 5 months ago

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

Jan 12, 2026, 10:00 AM EST - 5 months ago

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

Jan 11, 2026, 10:48 PM EST - 5 months ago

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

Jan 7, 2026, 1:49 PM EST - 5 months ago

Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera

ZTS ETN

Jan 7, 2026, 8:00 AM EST - 5 months ago

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

EXEL

Jan 5, 2026, 7:25 PM EST - 5 months ago

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

Jan 5, 2026, 7:00 AM EST - 5 months ago

Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology

Dec 22, 2025, 8:00 AM EST - 6 months ago

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 6 months ago

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

Dec 16, 2025, 8:00 AM EST - 6 months ago

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

Dec 12, 2025, 8:00 AM EST - 6 months ago

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

Dec 11, 2025, 10:37 AM EST - 6 months ago

Eight stock picks to play one of the healthiest corners of the market

ALNY ASND INSM MASI PODD UNH WGS

Dec 10, 2025, 7:57 PM EST - 6 months ago

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

Dec 9, 2025, 8:00 AM EST - 6 months ago

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

Dec 5, 2025, 7:00 AM EST - 6 months ago

Natera Acquires Foresight Diagnostics

Dec 5, 2025, 7:00 AM EST - 6 months ago

Natera Registration statement: Registration Filing

Dec 3, 2025, 8:00 AM EST - 7 months ago

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Dec 3, 2025, 8:00 AM EST - 7 months ago

Natera Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 8:00 AM EST - 7 months ago

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

Nov 19, 2025, 10:00 AM EST - 7 months ago

Natera Transcript: Wolfe Research Healthcare Conference 2025

Nov 19, 2025, 8:00 AM EST - 7 months ago

Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month

SM07 Jun. 18 at 1:50 PM

$NTRA This is another C Wood’s super hyped stock with a SP doomed to collapse all of a sudden.

2 · Reply

Georgii Jun. 18 at 8:10 AM

$NTRA

0 · Reply

JFDI Jun. 17 at 7:01 PM

$NTRA B/O

0 · Reply

Bio4 Jun. 17 at 6:05 PM

$CYDY $NTRA https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-nateras-cytodyn-ctdna-tie-up-and-board-refresh-reframing/amp

4 · Reply

JFDI Jun. 17 at 1:59 PM

$IBB $VRTX breaking out, AMGN & ILMN tee’d up on the 10d. $RVMD & $NTRA gorgeous sets up here. IBB & XBI looking good. Catalyst? Probably Ai.. ?

1 · Reply

FibonacciTrader_ Jun. 16 at 9:19 PM

1 · Reply

MorganHoratio Jun. 16 at 7:36 PM

0 · Reply

B2iDigital Jun. 16 at 3:16 AM

2 · Reply

TheBullishTrade Jun. 15 at 3:24 PM

0 · Reply

Estimize Jun. 15 at 11:06 AM

Wall St is expecting -0.49 EPS for $NTRA Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/ntra?chart=historical&metric_name=eps&utm_c

0 · Reply

BioHunter1 Jun. 12 at 6:32 PM

$NTRA The markets are for the shorts these days. Time for me to get out of EVERYTHING

0 · Reply

quantumapex Jun. 11 at 12:39 PM

$CYDY all I gotta say is WOW. This team is delivering. Collaboration with $NTRA 20 plus billion pharma and now collaboration with Weill Cornell Medicine the biomedical research unit of Cornell University. All in the same week. Talk about silencing “this is a scam” stupid talk we have dealt with for years.

0 · Reply

SuperGreenToday Jun. 10 at 10:05 PM

$NTRA Share Price: $216.58 Contract Selected: Sep 18, 2026 $220 Calls Buy Zone: $20.91 – $25.83 Target Zone: $39.17 – $47.87 Potential Upside: 77% ROI Time to Expiration: 99 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Georgii Jun. 10 at 8:53 AM

$NTRA

0 · Reply

quantumapex Jun. 9 at 5:22 PM

$CYDY The FDA almost exclusively grants accelerated approval for colorectal cancer when the drug targets a specific genetic mutation or biomarker where few options exist.2. High Magnitude and Durability of ResponseThe "Wow" Factor: The ORR cannot just be a minor improvement; it must be substantially higher than historical controls (e.g., an ORR of 30–40% vs. the 10% expected from late-line standard chemotherapy).Duration of Response (DOR): The tumors must stay small for a meaningful period (typically a median DOR of 6 months or longer). A high ORR where tumors grow back after a few weeks will be rejected And this is where $NTRA becomes a critical piece to the equation Back to you. Jay. Dr.Jay

1 · Reply

Livingeasy Jun. 5 at 12:52 PM

$CYDY Saving lives 🌻 Now Clover Study 🍀 fully Enrolled and $NTRA watching it in real blood draws as the tumors shrink. This is a God Sent to this Patients with Colon Cancer - the Lucky Ones!

0 · Reply

Ftrade24 Jun. 4 at 9:30 PM

$CYDY With Natera ($NTRA) to use their Signatera MRD platform for the CLOVER mCRC study. Why this matters for the bull case: Data Validation: Using Natera’s 2M+ plasma timepoint database gives CytoDyn independent, institutional-grade validation of their ctDNA response data. Precision Medicine: They aren't just looking at tumor size; they are using world-class diagnostic tools to prove "molecular response." Full Enrollment: CLOVER study is fully enrolled and now being analyzed with top-tier tools. Big Pharma Backing: ICIs are being supplied for free for these trials—Big Pharma is watching and supporting. Still waiting on the first Alzheimer’s patient enrollment—could happen any day now. The science is holding up, and the institutional partnerships are scaling. The FTD/market structure issues remain a major disconnect from the clinical progress. Currently holding and watching for the CLOVER data readout. What’s everyone’s take on the $NTRA partnership? #Biotech #Oncology #Investing #SmallCap

0 · Reply

Nyasaland Jun. 4 at 8:31 PM

$CYDY Cathie woods has 10% position in $ABSI which is on a tear. $146 million shares of Natera $NTRA . Wait until she gets eyeballs on us and many many other people.

1 · Reply

WAJeff Jun. 4 at 5:46 PM

$NTRA Been here a long time and just added more

0 · Reply

GhostofCytomight Jun. 4 at 5:19 PM

$CYDY $NTRA

0 · Reply

GhostofCytomight Jun. 4 at 5:15 PM

$NTRA $CYDY When Dr. KASI shows that Nateras CTDNA test that dropped in 100% of patients within week two correlates to ORR,CYDY and Natera are going to FLY‼️

1 · Reply

BioHunter1 Jun. 4 at 4:42 PM

$NTRA $CYDY For information check; https://www.reddit.com/r/Livimmune/s/oJRDhxmAs9

0 · Reply

Market Cap	32.43B
Revenue (ttm)	2.31B
Net Income (ttm)	-208.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9.03%
Debt to Equity Ratio	0.05

Volume	2,630,700
Avg Vol	1,515,304
Day's Range	N/A - N/A
Shares Out	143.22M
Stochastic %K	80%
Beta	1.56
Analysts	Strong Sell
Price Target	$258.16